// App-Quantinova.ai

201 : A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod (TASQ) in patients (pts) with mCRPC responsive to or stabilized during first-line docetaxel chemotherapy.

Researchers

Presenter

  • Karim Fizazi

Principal Investigators

  • Lisa Sengelv

  • Mette Moe

  • Sylvain Ladoire

  • Antoine Thiery- Vuillemin

  • Aude Flechon

  • Roberto Sabbatini

  • Joaquim Bellmunt

  • Miguel Angel Climent

  • Simon Chowdhury

  • Herlinde Dumez

  • Michaela Matouskova

  • Nicolas Penel

  • Sigita Liutkauskiene

  • Lech Stachurski

  • Cora N. Sternberg

  • Frederique Baton

  • Nathalie Germann

  • Gedske Daugaard

Medical Centers

  • Institut Gustave Roussy, University of Paris Sud, Villejuif, France

  • Faculty of Medicine, Vilnius University, Vilnius, Lithuania

  • Department of Oncology, Odense University Hospital, Odense, Denmark

  • Aalborg Hospital, Aalborg, Denmark

  • Georges-Francois Leclerc Cancer Center, Dijon, France

  • Medical Oncology Unit, CHU Minjoz, Besancon, France

  • Centre Leon Berard, Lyon, France

  • Azienda Ospedaliero-Universitaria, Udine, Italy

  • Hospital Del Mar, Barcelona, Spain

  • Oncología Médica, Fundación Instituto Valenciano de Oncología, Valencia, Spain

  • Medical Oncology Department, Guys and St. Thomas NHS Foundation Trust, London, United Kingdom

  • Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium

  • Gyncentrum, Prague, Czech Republic

  • Centre Oscar Lambret ? General Oncology Department, Lille, France

  • Lithuanian University of Health Sciences, Kaunas, Lithuania

  • Gabinet Urologiczny, Gdansk, Poland

  • San Camillo-Forlanini Hospital, Rome, Italy

  • Research and Development, Ipsen, Les Ulis, France

  • IPSEN INNOVATION, LES ULIS, France

  • Copenhagen University Hospital, Copenhagen, Denmark

Locations

  • France

  • Lithuania

  • Denmark

  • Italy

  • Spain

  • United Kingdom

  • Belgium

  • Czech Republic

  • Poland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Tasquinimod

  • Docetaxel

  • Epimorph

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • NCT01234311

  • NCT01732549

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved